Articles related to TARGETED THERAPIES

The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.

Uncover the potential of dupilumab in managing COPD patients with type 2 inflammation as this Phase 3 trial reveals fewer exacerbations, improved lung function, and enhanced life quality among the treated cohort.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

Recent advancements in AI are driving personalized treatment approaches for localized prostate cancer. This study highlights an AI-based model that could guide the application of ADT with radiotherapy, refining treatment strategies and improving patient outcomes.

Clinicians are eyeing the increased survival odds associated with Tagrisso, a targeted therapy for early-stage NSCLC patients. This revelation may shift the narrative on post-operative treatment protocols, promoting wider acceptance in oncological circles.

Significant progress has been made in the last 20 years in the identification of therapeutically relevant oncogenic drivers in NSCLC. These oncogenic drivers have been the focus of targeted medicines that have been created to offer enhanced tailored treatment for NSCLC. To improve the choice of patient-specific treatment, an oral presentation at the 2023 ONA Summit Live Virtual Meeting compared guideline-directed targeted therapies based on patient and tumor characteristics. It also described collaborative strategies for managing therapy-related adverse events for this patient population. Key molecular characteristics in advanced NSCLC were also discussed, along with their relationships to current and emerging targeted therapies.